HK46196A - Treatment of leukocyte dysfunction with gm-csf - Google Patents

Treatment of leukocyte dysfunction with gm-csf Download PDF

Info

Publication number
HK46196A
HK46196A HK46196A HK46196A HK46196A HK 46196 A HK46196 A HK 46196A HK 46196 A HK46196 A HK 46196A HK 46196 A HK46196 A HK 46196A HK 46196 A HK46196 A HK 46196A
Authority
HK
Hong Kong
Prior art keywords
csf
dysfunction
leukocyte
thermal injury
patients
Prior art date
Application number
HK46196A
Other languages
German (de)
English (en)
Inventor
M Bonnem Eric
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of HK46196A publication Critical patent/HK46196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • External Artificial Organs (AREA)

Claims (4)

  1. Utilisation de GM-CSF pour la fabrication d'un médicament à utiliser dans une méthode de traitement d'un mammifère présentant un disfonctionnement leucocytaire qui est associé à un traumatisme physique par administration, audit mammifère, d'une quantité efficace de GM-CSF pour potientaliser la fonction desdits leucocytes.
  2. Utilisation selon la revendication 1, où GM-CSF est GM-CSF humain recombinant.
  3. Utilisation selon la revendication 1 ou la revendication 2, où le médicament est sous une forme appropriée pour une administration par infusion ou injection intraveineuse.
  4. Utilisation selon toute revendication précédente, où le traumatisme physique est une blessure thermique.
HK46196A 1989-01-30 1996-03-14 Treatment of leukocyte dysfunction with gm-csf HK46196A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30439189A 1989-01-30 1989-01-30

Publications (1)

Publication Number Publication Date
HK46196A true HK46196A (en) 1996-03-22

Family

ID=23176323

Family Applications (1)

Application Number Title Priority Date Filing Date
HK46196A HK46196A (en) 1989-01-30 1996-03-14 Treatment of leukocyte dysfunction with gm-csf

Country Status (21)

Country Link
US (1) US5178855A (fr)
EP (2) EP0382381B1 (fr)
JP (1) JPH0651640B2 (fr)
KR (1) KR0137361B1 (fr)
AT (1) ATE89737T1 (fr)
AU (1) AU633054B2 (fr)
CA (1) CA2045605C (fr)
DE (1) DE69001686T2 (fr)
DK (1) DK0382381T3 (fr)
ES (1) ES2055314T3 (fr)
FI (1) FI913625A0 (fr)
HK (1) HK46196A (fr)
HU (1) HU207229B (fr)
IE (1) IE64234B1 (fr)
IL (1) IL93219A (fr)
MY (1) MY105798A (fr)
NZ (1) NZ243953A (fr)
OA (1) OA09509A (fr)
PT (1) PT92995B (fr)
WO (1) WO1990008554A1 (fr)
ZA (1) ZA90600B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081104A1 (fr) * 1991-02-22 1992-08-23 Glenn Pierce Utilisation de gm-csf et g-csf pour accelerer la guerison des plaies
GB9120304D0 (en) * 1991-09-24 1991-11-06 Erba Carlo Spa Stable pharmaceutical compositions containing a granulocyte macrophage colony stimulating factor
EP0661057A4 (fr) * 1993-06-08 1997-09-03 Ajinomoto Kk Accelerateur de la proliferation des cellules hematopietiques.
EP0791061A4 (fr) * 1994-03-04 1998-07-15 Ludwig Inst Cancer Res Animaux a rupture genique ciblee
US5942253A (en) 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CA2673049C (fr) * 2006-12-22 2016-02-23 Novadel Pharma Inc. Preparations antinauseeuses a pulveriser, a usage oral, stables, et methodes associees
US7648379B2 (en) 2007-08-09 2010-01-19 Haworth, Inc. Modular electrical distribution system for a building

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5078996A (en) * 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
EP0238655A4 (fr) * 1985-10-03 1989-09-11 Biogen Nv Polypeptides semblables aux facteurs de stimulation de colonies de granulocytes-macrophages (gm-csf) et leurs procedes de production en quantites importantes dans des cellules microbiennes.
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
DE3686582T2 (de) * 1985-11-27 1993-01-28 Genetics Inst Behandlung einer krankheit vom aids-typ.
HU212277B (en) * 1986-05-06 1996-04-29 Genetics Inst Process for producing m-csf
US5162111A (en) * 1986-07-30 1992-11-10 Grabstein Kenneth H Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor
EP0276846A3 (fr) * 1987-01-29 1989-07-26 Zymogenetics, Inc. Dérivés du facteur stimulant des colonies
EP0318184A1 (fr) * 1987-11-12 1989-05-31 Schering Corporation Accélération de la formation d'os par le GM-CSF

Also Published As

Publication number Publication date
IL93219A (en) 1998-12-27
ATE89737T1 (de) 1993-06-15
IL93219A0 (en) 1990-11-05
CA2045605C (fr) 1997-02-11
ZA90600B (en) 1990-10-31
ES2055314T3 (es) 1994-08-16
JPH0651640B2 (ja) 1994-07-06
CA2045605A1 (fr) 1990-07-31
PT92995A (pt) 1990-07-31
IE64234B1 (en) 1995-07-26
HUT57607A (en) 1991-12-30
JPH03504980A (ja) 1991-10-31
HU207229B (en) 1993-03-29
FI913625A7 (fi) 1991-07-30
US5178855A (en) 1993-01-12
DE69001686T2 (de) 1993-09-02
AU633054B2 (en) 1993-01-21
KR910700069A (ko) 1991-03-13
OA09509A (en) 1992-11-15
IE900318L (en) 1990-07-30
PT92995B (pt) 1995-12-29
EP0382381A1 (fr) 1990-08-16
DK0382381T3 (da) 1993-07-12
EP0382381B1 (fr) 1993-05-26
DE69001686D1 (de) 1993-07-01
KR0137361B1 (ko) 1998-04-25
AU5048890A (en) 1990-08-24
FI913625A0 (fi) 1991-07-30
MY105798A (en) 1995-01-30
NZ243953A (en) 1997-06-24
WO1990008554A1 (fr) 1990-08-09
EP0455726A1 (fr) 1991-11-13

Similar Documents

Publication Publication Date Title
Baldwin et al. Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients.
EP0382381B1 (fr) Traitement des désordres leucocytaires par le GM-CSF
JP2805224B2 (ja) 血小板減少症治療剤
EP0246322B1 (fr) Traitement de maladies du type du sida
US20100221274A1 (en) Method of administering a thymosin alpha 1 peptide
EP0231819B1 (fr) Composé pharmaceutique pour le traitement de la leucémie myélogène
EP0406324B1 (fr) Amelioration du profil du cholesterol lipoproteinique par des facteurs stimulateurs de colonie hematopoietique
CN101528251A (zh) 用于预防和治疗糖尿病性周围神经病变的含有g-csf的治疗剂
AU630637B2 (en) Treatment of myelosuppression associated with acquired immune deficiency
CA2188871C (fr) Methode pour le traitement du psoriasis
MXPA00003401A (es) Tratamiento del carcinoma de celula renal.
JP2002179588A (ja) チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤
WO1993000921A1 (fr) Remede a l'osteoporose
EP0661057A1 (fr) Accelerateur de la proliferation des cellules hematopietiques
Tanaka et al. Preventive effects of interleukin 1 β for ACNU-induced myelosuppression in malignant brain tumors: the experimental and preliminary clinical studies
CN120168610A (zh) 一种白细胞介素-13在促进肌肉损伤后修复中的应用
Veldhuis et al. Interleukin 3: its role in the physiopathology of allergy and clinical use in oncology
WO1997021446A1 (fr) Composition pharmaceutique pour la protection des cellules souches hematopoietiques, et applications
HK1132461B (en) Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)